Aucubin mitigates the elevation of microglial aerobic glycolysis and inflammation in diabetic neuropathic pain via aldose reductase

Figure 2 Aucubin alleviate streptozotocin-induced diabetic neuropathic pain and anxiety-like behavior. A: Blood glucose level of the diabetic neuropathic pain diabetic neuropathic pain (DNP): Mice after aucubin treatment; B: Body weight of the DNP mice after aucubin treatment; C: Mechanical paw withdrawal threshold in mice; D: Thermal paw withdrawal latency in mice; E: Total distance traveled in the open field test (OFT); F: Distance traveled by mice in the central area in the OFT after streptozotocin streptozotocin (STZ): Injection; G: Total distance traveled in the elevated plus maze (EPM); H: Number of entries of mice into the open arms in the EPM after STZ injection. Data are presented as means ± SEM (n = 10). ^aP < 0.05, ^bP < 0.01 control (CON) + vehicle (Veh) vs STZ + Veh; ^cP < 0.05, dP < 0.01 STZ + Veh vs STZ + aucubin. CON: Control; STZ: Streptozotocin; Veh: Vehicle; Auc: Aucubin; PWT: Paw withdrawal threshold; OFT: Open field test; EPM: Elevated plus maze.